Latest News and Press Releases

Accepted Abstracts Include Real-World Experience with Oxbryta® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood...

Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy...

Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT)...

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2021, the compensation committee of GBT’s board...

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor...

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat die Gründung der GBT Foundation bekannt gegeben. Die Stiftung agiert als...

SOUTH SAN FRANCISCO, Calif., 14 sept. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics Inc. (GBT) (NASDAQ: GBT) a annoncé le lancement de sa Fondation, une organisation dédiée à améliorer la santé...

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of...

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT’s...

SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA)...